Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease:Opportunities and challenges  

作　　者：Chencheng Xie Naim Alkhouri Mohamed A Elfeki 

机构地区：[1]Department of Internal Medicine,University of South Dakota Sanford School of Medicine,Sioux Falls,SD 57105,United States [2]Department of Hepatology,Avera Mckennan University Hospital and Transplant Institute,Sioux Falls,SD 57105,United States [3]Department of Hepatology,Arizona Liver Health,Chandler,AZ 85712,United States [4]Department of Hepatology,Avera McKennan University Hospital and Transplant Institute,Sioux Falls,SD 57105,United States

出　　处：《World Journal of Hepatology》2024年第5期731-750,共20页世界肝病学杂志（英文版）（电子版）

摘　　要：Metabolic dysfunction-associated steatotic liver disease(MASLD)has become the most common chronic liver disease worldwide,paralleling the rising pandemic of obesity and type 2 diabetes.Due to the growing global health burden and com-plex pathogenesis of MASLD,a multifaceted and innovative therapeutic approach is needed.Incretin receptor agonists,which were initially developed for diabetes management,have emerged as promising candidates for MASLD treatment.This review describes the pathophysiological mechanisms and action sites of three major classes of incretin/glucagon receptor agonists:glucagon-like peptide-1 receptor agonists,glucose-dependent insulinotropic polypeptide receptor agonists,and glucagon receptor agonists.Incretins and glucagon directly or indirectly impact various organs,including the liver,brain,pancreas,gastro-intestinal tract,and adipose tissue.Thus,these agents significantly improve glycemic control and weight management and mitigate MASLD pathogenesis.Importantly,this study provides a summary of clinical trials analyzing the effect-iveness and safety of incretin receptor agonists in MASLD management and provides an in-depth analysis highlighting their beneficial effects on improving liver function,hepatic steatosis,and intrahepatic inflammation.There are emerging challenges associated with the use of these medications in the real world,particularly adverse events,drug-drug interactions,and barriers to access,which are discussed in detail.Additionally,this review highlights the evolving role of incretin receptor agonists in MASLD management and suggests future research directions.

关 键 词：Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Glucagon-like peptide-1 Glucose-dependent inulinotropic polypeptide GLUCAGON INCRETIN Receptor agonist 

分 类 号：R575.5[医药卫生—消化系统]